Assessment of the risk for venous thromboembolism among users of hormone replacement therapy

Drugs and Aging

Volumn 14, Issue 1, 1999, Pages 55-61

  Oger, Emmanuel ^a   Scarabin, Pierre Yves ^b,c  

^a SERVICE DE RHUMATOLOGIE   (France)

^b HÔPITAL BROUSSAIS   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; SEX HORMONE;

CASE CONTROL STUDY; DATA BASE; DOSE RESPONSE; FEMALE; HORMONE SUBSTITUTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; METHODOLOGY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TRANSDERMAL DRUG ADMINISTRATION; VEIN THROMBOSIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PULMONARY EMBOLISM; RISK ASSESSMENT; THROMBOEMBOLISM; TIME FACTORS; VENOUS THROMBOSIS;

EID: 0033014716     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199914010-00004     Document Type: Review

References (38)

1. 1. Lichtman R. Perimenopausal hormone replacement therapy: review of the literature. J Nurse Midwifery 1991; 36: 30-48
2. 2. Barzel U. Estrogen in the prevention and treatment of postmenopausal osteoporosis: a review. Am J Mod 1988; 85: 847-50
3. 3. Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on hone density in elderly women. N Engl J Med 1993; 329: 1141-6
4. 4. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1-9
5. 5. Lobo RA. Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol 1990; 75 Suppl. 4: 18S-25
6. 6. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861-7
7. 7. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses Heath Study. N Engl J Med 1991; 325: 756-62
8. 8. The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199-208
9. 9. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-61
10. 10. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37
11. 11. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-75
12. 12. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997; 350: 1047-59
13. 13. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1589-92
14. 14. The Coronary Drug Project Research Group. The coronary drug project: initial findings leading to modifications of its research protocol. JAMA 1970; 214: 1303-13
15. 15. Boston Collaborative Drug Surveillance Program, Boston University Medical Center. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 1974; 290: 15-9
16. 16. Petitti DB, Wingerd J, Pellegrin F, et al. Risk of vascular disease in women: smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 1979, 242: 1150-4
17. 17. Devor M, Barrett-Connor E, Renvall M, et al. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-82
18. 18. Duly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80
19. 19. Daly E, Vessey MP, Painter R, et al. Case-control study of venous thromboembolism risk in users of hormone replacement therapy [letter]. Lancet 1996; 348: 1027
20. 20. Jick H, Derby LE, Wald Myers M, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-3
21. 21. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-7
22. 22. Douketis JD, Ginsberg JS, Holbrook A, et al. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med 1997; 157: 1522-30
23. 23. Perez-Gutthann S, Garcia Rodriguez LA, Castellsague J, et al. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314: 796-800
24. 24. Hunt DL, McKibbon KA. Locating and appraising systematic reviews. Ann Intern Med 1997; 126: 532-8
25. 25. Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. Ann Intern Med 1997; 127: 531-7
26. 26. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30
27. 27. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2: 121-45
28. 28. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54: 74-9
29. 29. Grady D, Furberg C. Venous thromboembolic events associated with hormone replacement therapy [letter]. JAMA 1997; 278: 477
30. 30. Schafer AI. Hypercoagulable states: molecular genetics to clinical practice. Lancet 1994; 344: 1739-42
31. 31. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia. Thromb Haemost 1996; 76 (Pt 1): 651-2
32. 32. Caine YG, Bauer KA, Barzegar S. Coagulation activation following estrogen administration in postmenopausal women. Thromb Haemost 1992; 68: 392-5
33. 33. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler Thromb Vasc Biol 1097; 17: 3071-8
34. 34. Conard J, Samama M, Basdevant A, et al. Differential ATIH response to oral and parenteral administration of 17-β estradiol [letter]. Thromb Haemost 1983; 40: 245
35. 35. De Lignières B, Basdevant A, Thomas G, et al. Biological effects of estradiol-17β in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986; 62: 536-41
36. 36. The Writing group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double blind, placebo-controlled study. Thromb Haemost 1996; 75: 476-80
37. 37. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683-90
38. 38. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13